Cargando…

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox

BACKGROUND: Iron is required for cellular metabolism, and rapidly proliferating cancer cells require more of this essential nutrient. Therefore, iron regulation may well represent a new avenue for cancer therapy. We have reported, through in vitro and in vivo research involving pancreatic cancer cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amano, Shogo, Kaino, Seiji, Shinoda, Shuhei, Harima, Hirofumi, Matsumoto, Toshihiko, Fujisawa, Koichi, Takami, Taro, Yamamoto, Naoki, Yamasaki, Takahiro, Sakaida, Isao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374870/ https://www.ncbi.nlm.nih.gov/pubmed/32698792 http://dx.doi.org/10.1186/s12885-020-07167-8

Ejemplares similares

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2023)

Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
por: Shinoda, Shuhei, et al.
Publicado: (2018)

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo
por: Harima, Hirofumi, et al.
Publicado: (2016)

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells
por: Fujisawa, Koichi, et al.
Publicado: (2022)

EUS-guided antegrade stenting using a braided metal stent with a 6-Fr novel slim delivery system for malignant biliary stricture following Roux-en-Y reconstruction (with video)
por: Harima, Hirofumi, et al.
Publicado: (2020)

Profiling of the circadian metabolome in thioacetamide‐induced liver cirrhosis in mice
por: Fujisawa, Koichi, et al.
Publicado: (2017)

Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model
por: Tanabe, Norikazu, et al.
Publicado: (2017)

Metabolic Alterations in Spheroid-Cultured Hepatic Stellate Cells
por: Fujisawa, Koichi, et al.
Publicado: (2020)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Circadian variations in the liver metabolites of medaka (Oryzias latipes)
por: Fujisawa, Koichi, et al.
Publicado: (2016)

Evaluation of the effects of ascorbic acid on metabolism of human mesenchymal stem cells
por: Fujisawa, Koichi, et al.
Publicado: (2018)

Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver
por: Fujisawa, Koichi, et al.
Publicado: (2017)

Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model
por: Sasaki, Ryo, et al.
Publicado: (2020)

Seasonal variations in photoperiod affect hepatic metabolism of medaka (Oryzias latipes)
por: Fujisawa, Koichi, et al.
Publicado: (2021)

Metabolic Analysis of DFO-Resistant Huh7 Cells and Identification of Targets for Combination Therapy
por: Fujisawa, Koichi, et al.
Publicado: (2023)

Modulation of anti-cancer drug sensitivity through the regulation of mitochondrial activity by adenylate kinase 4
por: Fujisawa, Koichi, et al.
Publicado: (2016)

Efficacy of Contrast-enhanced Harmonic Endoscopic Ultrasonography in the Diagnosis of Pancreatic Ductal Carcinoma
por: Uekitani, Toshiyuki, et al.
Publicado: (2016)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

NUPR1 acts as a pro-survival factor in human bone marrow-derived mesenchymal stem cells and is induced by the hypoxia mimetic reagent deferoxamine
por: Matsunaga, Kazuhito, et al.
Publicado: (2019)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)

Evidence for a Role of the Transcriptional Regulator Maid in Tumorigenesis and Aging
por: Fujisawa, Koichi, et al.
Publicado: (2015)

Correction: Evidence for a Role of the Transcriptional Regulator Maid in Tumorigenesis and Aging
por: Fujisawa, Koichi, et al.
Publicado: (2015)

Iron regulation by hepatocytes and free radicals
por: Takami, Taro, et al.
Publicado: (2011)

Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
por: Saeki, Issei, et al.
Publicado: (2018)

Assessment of high-fat-diet-induced fatty liver in medaka
por: Fujisawa, Koichi, et al.
Publicado: (2018)

Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose
por: Fujisawa, Koichi, et al.
Publicado: (2021)

Evaluation of the Effects of Microgravity on Activated Primary Human Hepatic Stellate Cells
por: Fujisawa, Koichi, et al.
Publicado: (2022)

Effects of oral iron chelator deferasirox on human malignant lymphoma cells
por: Choi, Jong Gwon, et al.
Publicado: (2012)

EUS-guided antegrade metallic stent placement using the stent-in-stent method with a 6-Fr novel slim delivery system in a patient with malignant hilar biliary obstruction
por: Suenaga, Shigeyuki, et al.
Publicado: (2021)

Deferasirox, an iron-chelating agent, alleviates acute lung inflammation by inhibiting neutrophil activation and extracellular trap formation
por: Kono, Mari, et al.
Publicado: (2020)

A New Therapeutic Assessment Score for Advanced Hepatocellular Carcinoma Patients Receiving Hepatic Arterial Infusion Chemotherapy
por: Saeki, Issei, et al.
Publicado: (2015)

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
por: Iwamoto, Takuya, et al.
Publicado: (2016)

Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
por: Kim, Dae Sik, et al.
Publicado: (2016)

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease
por: Raj, Ashok, et al.
Publicado: (2022)

Liver regeneration therapy through the hepatic artery-infusion of cultured bone marrow cells in a canine liver fibrosis model
por: Nishimura, Tatsuro, et al.
Publicado: (2019)

Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2019)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ut101mi4f87g6e35useo1hje43